Cancer Supportive Care Drugs Market By Therapeutic Class - Global Industry Analysis And Forecast To 2027
Published On : March 2019 Pages : 170 Category: Pharma & Healthcare Report Code : HC032758
Cancer Supportive Care Drugs Market By Therapeutic Class (NSAIDs, G-CSFs, Opioids, ESAs, Bisphosphonates, Antiemetics and Other Therapeutic Classes) - Global Industry Analysis And Forecast To 2027
Industry Outlook
The supportive medications are sometimes utilized to diminish the harmful symptoms of the treatment related to cancer by securing certain organs or cells. These medications are not utilized to treatment of cancer. These medications are likewise known as protective medications. Therefore, the Cancer Supportive Care Drugs Market is anticipated to expand and has tremendous scope during the forecast period. The global Cancer Supportive Care Drugs Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
Based on Therapeutic Class the market is segmented into NSAIDs, G-CSFs, Opioids, ESAs, Bisphosphonates, Antiemetics and Other Therapeutic Classes. The G-CSFs is seen leading the market but will see a slower growth during the forecast period due to losses in the patents, lower utilization of the myelosuppressive chemotherapy, while the Antiemetics will show a substantial growth due to launch if new products.
Regional Insights
The North American region is leading the global Cancer Supportive Care Drugs Market with US leading the region due to more number of launches related to biosimilars, increasing utilization of biosimilars, etc.
Cancer Supportive Care Drugs Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Tesaro
- Amgen
- Heron Pharma
- Johnson & Johnson
- Merck
- Helsinn Healthcare
- Roche
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Cancer Supportive Care Drugs Market, By Therapeutic Class, Estimates and Forecast, 2017-2027 ($Million)
o NSAIDs
o G-CSFs
o Opioids
o ESAs
o Bisphosphonates
o Antiemetics
o Other Therapeutic Classes
o Cancer Supportive Care Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Cancer Supportive Care Drugs Market, By Country
o U.S. Cancer Supportive Care Drugs Market
o Canada Cancer Supportive Care Drugs Market
o Mexico Cancer Supportive Care Drugs Market
o Europe
§ Europe Cancer Supportive Care Drugs Market, By Country
o Germany Cancer Supportive Care Drugs Market
o UK Cancer Supportive Care Drugs Market
o France Cancer Supportive Care Drugs Market
o Russia Cancer Supportive Care Drugs Market
o Italy Cancer Supportive Care Drugs Market
o Rest of Europe Cancer Supportive Care Drugs Market
o Asia-Pacific
§ Asia-Pacific Cancer Supportive Care Drugs Market, By Country
o China Cancer Supportive Care Drugs Market
o Japan Cancer Supportive Care Drugs Market
o South Korea Cancer Supportive Care Drugs Market
o India Cancer Supportive Care Drugs Market
o Southeast Asia Cancer Supportive Care Drugs Market
o Rest of Asia-Pacific Cancer Supportive Care Drugs Market
o South America
§ South America Cancer Supportive Care Drugs Market, By Country
o Brazil Cancer Supportive Care Drugs Market
o Argentina Cancer Supportive Care Drugs Market
o Columbia Cancer Supportive Care Drugs Market
o Rest of South America Cancer Supportive Care Drugs Market
o Middle East and Africa
§ Middle East and Africa Cancer Supportive Care Drugs Market, By Country
o Saudi Arabia Cancer Supportive Care Drugs Market
o UAE Cancer Supportive Care Drugs Market
o Egypt Cancer Supportive Care Drugs Market
o Nigeria Cancer Supportive Care Drugs Market
o South Africa Cancer Supportive Care Drugs Market
o Rest of MEA Cancer Supportive Care Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Cancer Supportive Care Drugs Market, By Therapeutic Class
5.1. Introduction
5.2. Global Cancer Supportive Care Drugs Revenue and Market Share by Therapeutic Class (2017-2027)
5.2.1. Global Cancer Supportive Care Drugs Revenue and Revenue Share by Therapeutic Class (2017-2027)
5.3. NSAIDs
5.3.1. Global NSAIDs Revenue and Growth Rate (2017-2027)
5.4. G-CSFs
5.4.1. Global G-CSFs Revenue and Growth Rate (2017-2027)
5.5. Opioids
5.5.1. Global Opioids Revenue and Growth Rate (2017-2027)
5.6. ESAs
5.6.1. Global ESAs Revenue and Growth Rate (2017-2027)
5.7. Bisphosphonates
5.7.1. Global Bisphosphonates Revenue and Growth Rate (2017-2027)
5.8. Antiemetics
5.8.1. Global Antiemetics Revenue and Growth Rate (2017-2027)
5.9. Other Therapeutic Classes
5.9.1. Global Other Therapeutic Classes Revenue and Growth Rate (2017-2027)
6. Cancer Supportive Care Drugs Market, By Region
6.1. Introduction
6.2. Global Cancer Supportive Care Drugs Revenue and Market Share by Regions
6.2.1. Global Cancer Supportive Care Drugs Revenue by Regions (2017-2027)
6.3. North America Cancer Supportive Care Drugs by Countries
6.3.1. North America Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2027)
6.3.2. North America Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2027)
6.3.3. United States
6.3.3.1. United States Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.4. Canada
6.3.4.1. Canada Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.5. Mexico
6.3.5.1. Mexico Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4. Europe Cancer Supportive Care Drugs by Countries
6.4.1. Europe Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2027)
6.4.2. Europe Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2027)
6.4.3. Germany
6.4.3.1. Germany Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.4. France
6.4.4.1. France Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.5. UK
6.4.5.1. UK Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.6. Russia
6.4.6.1. Russia Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.7. Italy
6.4.7.1. Italy Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5. Asia-Pacific Cancer Supportive Care Drugs by Countries
6.5.1. Asia-Pacific Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2027)
6.5.2. Asia-Pacific Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2027)
6.5.3. China
6.5.3.1. China Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.4. Japan
6.5.4.1. Japan Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.5. Korea
6.5.5.1. Korea Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.6. India
6.5.6.1. India Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.6. South America Cancer Supportive Care Drugs by Countries
6.6.1. South America Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2027)
6.6.2. South America Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2027)
6.6.3. Brazil
6.6.3.1. Brazil Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.4. Argentina
6.6.4.1. Argentina Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.5. Columbia
6.6.5.1. Columbia Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7. Middle East and Africa Cancer Supportive Care Drugs by Countries
6.7.1. Middle East and Africa Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2027)
6.7.2. Middle East and Africa Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2027)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.5. Egypt
6.7.5.1. Egypt Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.6. Nigeria
6.7.6.1. Nigeria Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.7. South Africa
6.7.7.1. South Africa Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.8. Turkey
6.7.8.1. Turkey Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7. Company Profiles
7.1. Tesaro
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Financial Overview
7.2. Amgen
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Financial Overview
7.3. Heron Pharma
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Financial Overview
7.4. Johnson & Johnson
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Financial Overview
7.5. Merck
7.5.1. Business Overview
7.5.2. Service Portfolio
7.5.3. Strategic Developments
7.5.4. Financial Overview
7.6. Helsinn Healthcare
7.6.1. Business Overview
7.6.2. Service Portfolio
7.6.3. Strategic Developments
7.6.4. Financial Overview
7.7. Roche
7.7.1. Business Overview
7.7.2. Service Portfolio
7.7.3. Strategic Developments
7.7.4. Financial Overview
8. Global Cancer Supportive Care Drugs Market Competition, by Manufacturer
8.1. Global Cancer Supportive Care Drugs Revenue and Market Share by Manufacturer (2017-2017)
8.2. Global Cancer Supportive Care Drugs Price By Region (2017-2017)
8.3. Top 5 Cancer Supportive Care Drugs Manufacturer Market Share
8.4. Market Competition Trend
9. Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.1. Global Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Cancer Supportive Care Drugs Market Forecast by Regions (2017-2027)
9.2.1. North America Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.1.1. United States Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.1.2. Canada Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.1.3. Mexico Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.2. Europe Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.2.1. Germany Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.2.2. France Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.2.3. UK Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.2.4. Russia Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.2.5. Italy Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.3. Asia-Pacific Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.3.1. China Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.3.2. Japan Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.3.3. Korea Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.3.4. India Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.4. South America Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.4.1. Brazil Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.4.2. Argentina Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.4.3. Columbia Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.4.4. Rest of South America Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.5. Middle East and Africa Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.5.3. Egypt Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.5.4. Nigeria Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.5.5. South Africa Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.5.6. Turkey Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Cancer Supportive Care Drugs Market Forecast (2017-2027)
9.3. Cancer Supportive Care Drugs Market Forecast by Therapeutic Class (2017-2027)
9.3.1. Cancer Supportive Care Drugs Forecast by Therapeutic Class (2017-2027)
9.3.2. Cancer Supportive Care Drugs Market Share Forecast by Therapeutic Class (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Cancer Supportive Care Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Cancer Supportive Care Drugs Revenue and Revenue Share by Therapeutic Class (2017-2018)
Figure Global NSAIDs Revenue and Growth Rate (2017-2018)
Figure Global G-CSFs Revenue and Growth Rate (2017-2018)
Figure Global Opioids Revenue and Growth Rate (2017-2018)
Figure Global ESAs Revenue and Growth Rate (2017-2018)
Figure Global Bisphosphonates Revenue and Growth Rate (2017-2018)
Figure Global Antiemetics Revenue and Growth Rate (2017-2018)
Figure Global Other Therapeutic Classes Revenue and Growth Rate (2017-2018)
Table Global Cancer Supportive Care Drugs Revenue by Regions (2017-2018)
Figure North America Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure North America Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2018)
Figure North America Cancer Supportive Care Drugs by Countries (2017-2018)
Figure North America Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure United States Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Canada Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Mexico Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Europe Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Cancer Supportive Care Drugs by Countries (2017-2018)
Figure Europe Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Germany Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure France Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure UK Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Russia Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Italy Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Rest of Europe Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Cancer Supportive Care Drugs by Countries (2017-2018)
Figure Asia-Pacific Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure China Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Japan Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Korea Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure India Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Southeast Asia Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure South America Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2018)
Figure South America Cancer Supportive Care Drugs by Countries (2017-2018)
Figure South America Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Brazil Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Argentina Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Columbia Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Rest of South America Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Cancer Supportive Care Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Cancer Supportive Care Drugs by Countries (2017-2018)
Figure Middle East and Africa Cancer Supportive Care Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Egypt Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Nigeria Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure South Africa Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Turkey Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Cancer Supportive Care Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Tesaro Cancer Supportive Care Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Amgen Cancer Supportive Care Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Heron Pharma Cancer Supportive Care Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Johnson & Johnson Cancer Supportive Care Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Merck Cancer Supportive Care Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Helsinn Healthcare Cancer Supportive Care Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Roche Cancer Supportive Care Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Cancer Supportive Care Drugs Market Share by Manufacturer
Figure Global Cancer Supportive Care Drugs Revenue and Market Share by Manufacturer
Table Global Cancer Supportive Care Drugs Price by Region (2017-2017)
Figure Top 5 Cancer Supportive Care Drugs Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Cancer Supportive Care Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Cancer Supportive Care Drugs Market Forecast by Regions (2018-2025)
Figure North America Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure United States Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Canada Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Mexico Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Europe Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Germany Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure France Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure UK Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Russia Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Italy Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Rest of Europe Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure China Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Japan Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Korea Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure India Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Southeast Asia Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure South America Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Brazil Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Argentina Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Columbia Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Rest of South America Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Egypt Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Nigeria Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure South Africa Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Turkey Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Cancer Supportive Care Drugs Market Forecast (2018-2025)
Figure Global Cancer Supportive Care Drugs Forecast by Therapeutic Class (2018-2025)
Figure Global Cancer Supportive Care Drugs Market Share Forecast by Therapeutic Class (2018-2025)
Figure Global Cancer Supportive Care Drugs Forecast by Therapeutic Class (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|